Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis

  1. J. Colquitt1,*,
  2. P. Royle2,
  3. N. Waugh2

Article first published online: 26 SEP 2003

DOI: 10.1046/j.1464-5491.2003.01018.x

Issue

Diabetic Medicine

Diabetic Medicine

Volume 20, Issue 10, pages 863–866, October 2003

Additional Information

How to Cite

Colquitt, J., Royle, P. and Waugh, N. (2003), Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabetic Medicine, 20: 863–866. doi: 10.1046/j.1464-5491.2003.01018.x

Author Information

  1. 1

    Southampton Health Technology Assessments Centre, University of Southampton, Southampton, and

  2. 2

    Department of Public Health, University of Aberdeen, Aberdeen, UK

*Correspondence to: Dr Jill Colquitt, Southampton Health Technology Assessments Centre, University of Southampton, Mailpoint 728, Boldrewood, Southampton SO16 7PX, UK. E-mail: j.colquitt@soton.ac.uk

Publication History

  1. Issue published online: 26 SEP 2003
  2. Article first published online: 26 SEP 2003
  3. Accepted 3 April 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (183K)

Keywords:

  • analogue insulin;
  • CSII;
  • meta-analysis;
  • glycated haemoglobin;
  • hypoglycaemia

Abstract

Aims  The properties of rapid-acting insulin analogues are thought to be particularly appropriate for use in continuous subcutaneous insulin infusion (CSII) or insulin pump therapy. We conducted a systematic review and meta-analysis of trials comparing rapid-acting insulin analogues with soluble insulin in CSII.

Methods  The following databases were searched (last search June 2002): MEDLINE 1985–2002; Embase 1980–2002; PubMed internet version, records added June 2001 to June 2002; Science Citation Index 1990–2002; BIOSIS 1999–2002; Web of Science Proceedings 1990–2002; and the Cochrane Library, including DARE and the HTA databases. Randomized controlled trials and crossover studies with at least 10 weeks on each treatment were included. Data extraction and quality assessment were undertaken by one reviewer and checked by a second. A meta-analysis was undertaken using a random effects model.

Results  A significant improvement of 0.26% (95% confidence interval −0.47, −0.06%) in glycated haemoglobin was demonstrated with lispro. Some studies reported fewer hypoglycaemic episodes with analogue insulin but this varied according to the definitions used. No differences in insulin dosage or weight were seen. Two studies reported patient preference, with analogues preferred in both. The extra cost per annum ranges from £72 (at 40 units per day) to £150 (at 84 units per day).

Conclusions  Insulin analogues result in a modest but significant reduction in HbA1c compared with soluble insulin when used in CSII, and are preferred by patients.

View Full Article (HTML) Get PDF (183K)